ArticleBrain pathology (Zurich, Switzerland)2007
DNA hypermethylation and aberrant expression of the EMP3 gene at 19q13.3 in Human Gliomas.
Article in Brain pathology (Zurich, Switzerland), 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 52 citations in OpenAlex.
- EMP3: A promising biomarker for tumor prognosis and targeted cancer therapy.Cancer biomarkers : section A of Disease markers · 2024Review
- Integration of Multi-Omics Data for the Classification of Glioma Types and Identification of Novel Biomarkers.Bioinformatics and biology insights · 2024Article
- The Multifunctional Role of EMP3 in the Regulation of Membrane Receptors Associated with IDH-Wild-Type Glioblastoma.International journal of molecular sciences · 2021Review
- Potential Epigenetic-Based Therapeutic Targets for Glioma.Frontiers in molecular neuroscience · 2018Review
- Identification of potential key genes associated with glioblastoma based on the gene expression profile.Oncology letters · 2017Article
- Epithelial membrane protein 3 regulates TGF-β signaling activation in CD44-high glioblastoma.Oncotarget · 2017Article
- Targeting EMP3 suppresses proliferation and invasion of hepatocellular carcinoma cells through inactivation of PI3K/Akt pathway.Oncotarget · 2015Article
- Review of the GAS3 Family of Proteins and their Relevance to Cancer.Critical reviews in oncogenesis · 2015Review
- Promoter hypermethylation of the EMP3 gene in a series of 229 human gliomas.BioMed research international · 2013Article
- Unique biology of gliomas: challenges and opportunities.Trends in neurosciences · 2012Review
- Unraveling the glioma epigenome: from molecular mechanisms to novel biomarkers and therapeutic targets.Brain pathology (Zurich, Switzerland) · 2011Review
- DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression.Neuro-oncology · 2011Article
- Distinct patterns of 1p and 19q alterations identify subtypes of human gliomas that have different prognoses.Neuro-oncology · 2010Article
- Differential proteome analysis of human gliomas stratified for loss of heterozygosity on chromosomal arms 1p and 19q.Neuro-oncology · 2010Article
- Epigenetics of neurological cancers.Future oncology (London, England) · 2009Review
- EMP3 overexpression in primary breast carcinomas is not associated with epigenetic aberrations.Journal of Korean medical science · 2009Article
- Molecular neuropathology of gliomas.International journal of molecular sciences · 2009Review
- Epigenetic changes in gliomas.Cancer biology & therapy · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allelic losses on 19q are found in the majority of oligodendroglial tumors and approximately one-third of diffuse astrocytomas. However, the tumor suppressor genes (TSG) on 19q are still elusive. Using cDNA microarray expression profiling, EMP3 at 19q13.3 was among those genes showing the most pronounced expression differences. In line with this, other authors reported EMP3 as being epigenetically silenced in neuroblastomas and astrocytomas. To further investigate EMP3 as a TSG candidate on 19q13.3, we performed molecular analysis of this gene in 162 human gliomas. Mutation analysis did not reveal EMP3 alteration in 132 gliomas. In oligodendroglial tumors, we found that aberrant methylation in the 5'-region of EMP3 was significantly associated with reduced mRNA expression and LOH 19q. In astrocytomas, EMP3 hypermethylation was also paralleled by reduced expression but was independent of the 19q status. EMP3 hypermethylation was detected in more than 80% of diffuse, anaplastic astrocytomas and secondary glioblastomas. Primary glioblastomas, however, mostly lacked EMP3 hypermethylation and frequently overexpressed EMP3. Our data corroborate that oligodendroglial and astrocytic gliomas often show EMP3 hypermethylation and aberrant expression. Furthermore, our findings suggest that primary and secondary glioblastomas are not only characterized by distinct genetic profiles but also differ in their epigenetic aberrations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.